These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 34857028)

  • 1. Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer.
    Ghamlouch H; Boyle EM; Blaney P; Wang Y; Choi J; Williams L; Bauer M; Auclair D; Bruno B; Walker BA; Davies FE; Morgan GJ
    J Exp Clin Cancer Res; 2021 Dec; 40(1):380. PubMed ID: 34857028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation.
    Ren Z; Ahn JH; Liu H; Tsai YH; Bhanu NV; Koss B; Allison DF; Ma A; Storey AJ; Wang P; Mackintosh SG; Edmondson RD; Groen RWJ; Martens AC; Garcia BA; Tackett AJ; Jin J; Cai L; Zheng D; Wang GG
    Blood; 2019 Oct; 134(14):1176-1189. PubMed ID: 31383640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PHF19 inhibition as a therapeutic target in multiple myeloma.
    Schinke CD; Bird JT; Qu P; Yaccoby S; Lyzogubov VV; Shelton R; Ling W; Boyle EM; Deshpande S; Byrum SD; Washam C; Mackintosh S; Stephens O; Thanendrarajan S; Zangari M; Shaughnessy J; Zhan F; Barlogie B; van Rhee F; Walker BA
    Curr Res Transl Med; 2021 Jul; 69(3):103290. PubMed ID: 33894670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a.
    Yu T; Du C; Ma X; Sui W; Yu Z; Liu L; Zhao L; Li Z; Xu J; Wei X; Zhou W; Deng S; Zou D; An G; Tai YT; Tricot G; Anderson KC; Qiu L; Zhan F; Hao M
    Mol Cancer Res; 2020 Jul; 18(7):1063-1073. PubMed ID: 32312841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PHD finger protein 19 expression in multiple myeloma: Association with clinical features, induction therapy outcome, disease progression, and survival.
    Li Y; Gong J; Zhang L
    J Clin Lab Anal; 2021 Sep; 35(9):e23910. PubMed ID: 34390275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PHF19 mediated regulation of proliferation and invasiveness in prostate cancer cells.
    Jain P; Ballare C; Blanco E; Vizan P; Di Croce L
    Elife; 2020 Mar; 9():. PubMed ID: 32155117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of PHF19 inhibits cell growth and migration in gastric cancer.
    Wang H; Xu P; Sun G; Lv J; Cao J; Xu Z
    Scand J Gastroenterol; 2020 Jun; 55(6):687-693. PubMed ID: 32449434
    [No Abstract]   [Full Text] [Related]  

  • 8. [EZH2 is therapeutic target for personalized treatment in multiple myeloma].
    Herviou L; Cavalli G; Moreaux J
    Bull Cancer; 2018 Sep; 105(9):804-819. PubMed ID: 30041976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phf19 links methylated Lys36 of histone H3 to regulation of Polycomb activity.
    Ballaré C; Lange M; Lapinaite A; Martin GM; Morey L; Pascual G; Liefke R; Simon B; Shi Y; Gozani O; Carlomagno T; Benitah SA; Di Croce L
    Nat Struct Mol Biol; 2012 Dec; 19(12):1257-65. PubMed ID: 23104054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting.
    Cai L; Rothbart SB; Lu R; Xu B; Chen WY; Tripathy A; Rockowitz S; Zheng D; Patel DJ; Allis CD; Strahl BD; Song J; Wang GG
    Mol Cell; 2013 Feb; 49(3):571-82. PubMed ID: 23273982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease.
    Mason MJ; Schinke C; Eng CLP; Towfic F; Gruber F; Dervan A; White BS; Pratapa A; Guan Y; Chen H; Cui Y; Li B; Yu T; Chaibub Neto E; Mavrommatis K; Ortiz M; Lyzogubov V; Bisht K; Dai HY; Schmitz F; Flynt E; Dan Rozelle ; Danziger SA; Ratushny A; ; Dalton WS; Goldschmidt H; Avet-Loiseau H; Samur M; Hayete B; Sonneveld P; Shain KH; Munshi N; Auclair D; Hose D; Morgan G; Trotter M; Bassett D; Goke J; Walker BA; Thakurta A; Guinney J
    Leukemia; 2020 Jul; 34(7):1866-1874. PubMed ID: 32060406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microRNA-124a suppresses PHF19 over-expression, EZH2 hyper-activation, and aberrant cell proliferation in human glioma.
    Lu J; Ji H; Tang H; Xu Z
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1610-1617. PubMed ID: 30131250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
    Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
    Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
    Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
    Front Immunol; 2021; 12():781087. PubMed ID: 35069553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for histone variant H3tK27me3 recognition by PHF1 and PHF19.
    Dong C; Nakagawa R; Oyama K; Yamamoto Y; Zhang W; Dong A; Li Y; Yoshimura Y; Kamiya H; Nakayama JI; Ueda J; Min J
    Elife; 2020 Sep; 9():. PubMed ID: 32869745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-Specific Tumour Suppressor and Oncogenic Activities of the Polycomb-like Protein MTF2.
    Ngubo M; Moradi F; Ito CY; Stanford WL
    Genes (Basel); 2023 Sep; 14(10):. PubMed ID: 37895228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PHD Finger Protein 19 Promotes Cardiac Hypertrophy via Epigenetically Regulating SIRT2.
    Gu W; Cheng Y; Wang S; Sun T; Li Z
    Cardiovasc Toxicol; 2021 Jun; 21(6):451-461. PubMed ID: 33611744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation.
    Adamik J; Jin S; Sun Q; Zhang P; Weiss KR; Anderson JL; Silbermann R; Roodman GD; Galson DL
    Mol Cancer Res; 2017 Apr; 15(4):405-417. PubMed ID: 28119431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
    Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
    Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells.
    García-Montolio M; Ballaré C; Blanco E; Gutiérrez A; Aranda S; Gómez A; Kok CH; Yeung DT; Hughes TP; Vizán P; Di Croce L
    Front Cell Dev Biol; 2021; 9():655201. PubMed ID: 33996816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.